Omalizumab in the management of patients with allergic (IgE-mediated) asthma

References

• BurneyPThe changing prevalence of asthma?Thorax200257Suppl 2II36II3912364709
   PubMedGoogle Scholar
• CourtCSCookDGStrachanDPComparative epidemiology of atopic and non-atopic wheeze and diagnosed asthma in a national sample of English adultsThorax20025795195712403877
   PubMed Web of Science ®Google Scholar
• SporikRPlatts-MillsTAAllergen exposure and the development of asthmaThorax200156Suppl 2ii58ii6311514708
   PubMedGoogle Scholar
• Platts-MillsTAThe role of immunoglobulin E in allergy and asthmaAm J Respir Crit Care Med2001164S1S511704610
   PubMed Web of Science ®Google Scholar
• PrussinCMetcalfeDDIgE, mast cells, basophils, and eosinophilsJ Allergy Clin Immunol2003111S486S49412592295
   PubMed Web of Science ®Google Scholar
• GleichGJMechanisms of eosinophil-associated inflammationJ Allergy Clin Immunol200010565166310756213
   PubMed Web of Science ®Google Scholar
• JaffarZRobertsKPanditALinsleyPDjukanovićRHolgateSB7 costimulation is required for IL-5 and IL-13 secretion by bronchial biopsy tissue of atopic asthmatic subjects in response to allergen stimulationAm J Respir Cell Mol Biol1999201531629870929
   PubMed Web of Science ®Google Scholar
• BousquetJVignolaAMDemolyPLinks between rhinitis and asthmaAllergy20035869170612859545
   PubMed Web of Science ®Google Scholar
• SandstromTTargeting immunoglobulin E as a novel treatment for asthmaCurr Allergy Asthma Rep2005510911515683610
   PubMed Web of Science ®Google Scholar
• BreedveldFCTherapeutic monoclonal antibodiesLancet200035573574010703815
   PubMed Web of Science ®Google Scholar
• HookWAZinsserFUBerensteinEHSiraganianRPMonoclonal antibodies defining epitopes on human IgEMol Immunol1991286316391713647
   PubMed Web of Science ®Google Scholar
• PrestaLShieldsRO’ConnellLThe binding site on human immunoglobulin E for its high affinity receptorJ Biol Chem199426926368263737929356
   PubMed Web of Science ®Google Scholar
• PrestaLGLahrSJShieldsRLHumanization of an antibody directed against IgEJ Immunol1993151262326328360482
   PubMed Web of Science ®Google Scholar
• ShieldsRLWhetherWRZioncheckKInhibition of allergic reactions with antibodies to IgEInt Arch Allergy Immunol19951073083127613156
   PubMed Web of Science ®Google Scholar
• BusseWCorrenJLanierBQOmalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJ Allergy Clin Immunol200110818419011496232
   PubMed Web of Science ®Google Scholar
• SolèrMMatzJTownleyRThe anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmaticsEur Respir J20011825426111529281
   PubMed Web of Science ®Google Scholar
• ÄdelrothERakSHaahtelaTRecombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitisJ Allergy Clin Immunol200010625325910932067
   PubMed Web of Science ®Google Scholar
• CasaleTBCondemiJLaForceCEffect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trialJAMA20012862956296711743836
   PubMed Web of Science ®Google Scholar
• CorrenJDiaz-SanchezDSaxonAEffects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesisAnn Allergy Asthma Immunol20049324324815478383
   PubMed Web of Science ®Google Scholar
• LinHBoeselKMGriffithDTOmalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophilsJ Allergy Clin Immunol200411329730214767445
   PubMed Web of Science ®Google Scholar
• MacGlashanDWJrBochnerBSAdelmanDCDown-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibodyJ Immunol1997158143814459013989
   PubMed Web of Science ®Google Scholar
• BeckLAMarcotteGVMacGlashanDTogiasASainiSOmalizumab-induced reductions in mast cell Fcepsilon RI expression and functionJ Allergy Clin Immunol200411452753015356552
   PubMed Web of Science ®Google Scholar
• DjukanovićRWilsonSJKraftMEffects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthmaAm J Respir Crit Care Med200417058359315172898
   PubMed Web of Science ®Google Scholar
• HayekBHeilPMLaimerMMaurerDHultschTStinglGOmalizumab-induced downregulation of IgE/ FcɛRI on dendritic cells in patients with atopic dermatitisXXIII EAACI Congress2004224744 (Abstract).
   Google Scholar
• FahyJVFlemingHEWongHHThe effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjectsAm J Respir Crit Care Med1997155182818349196082
   PubMed Web of Science ®Google Scholar
• BouletLPChapmanKRCôtéJInhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic responseAm J Respir Crit Care Med1997155183518409196083
   PubMed Web of Science ®Google Scholar
• van RensenELJEvertseCEvan SchadewijkAMAnti-IgE-induced reduction in airway responses to inhaled allergen is paralleled by decreased eosinophilia in bronchial biopsies and sputum in patients with asthmaAllergy200964728019076931
   PubMed Web of Science ®Google Scholar
• Genentech IncOmalizumab (Xolair®) full prescribing information (US)72007 Available at http://www.gene.com/gene/products/information/immunological/xolair/insert.jsp. Accessed 6 March 2009.
   Google Scholar
• European Medicines Agency (EMEA)Omalizumab (Xolair®) full prescribing information (EU)52007 Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/Xolair/H-606-PI-en.pdf. Accessed 6 March 2009.
   Google Scholar
• AyresJGHigginsBChilversERAyreGBloggMFoxHEfficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthmaAllergy20045970170815180756
   PubMed Web of Science ®Google Scholar
• HolgateSTChuchalinAGHébertJEfficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthmaClin Exp Allergy20043463263815080818
   PubMed Web of Science ®Google Scholar
• VignolaAMHumbertMBousquetJEfficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLARAllergy20045970971715180757
   PubMed Web of Science ®Google Scholar
• HochhausGBrookmanLFoxHPharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthmaCurr Med Res Opin20031949149814594521
   PubMed Web of Science ®Google Scholar
• HumbertMBeasleyRAyresJBenefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy20056030931615679715
   PubMed Web of Science ®Google Scholar
• BousquetJCabreraPBerkmanNThe effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthmaAllergy20056030230815679714
   PubMed Web of Science ®Google Scholar
• Global Initiative for AsthmaGlobal strategy for asthma management and prevention Issued January 1995 (NIH Publication No. 02-3659); updated 2002, 2003, 2004, 2005, 2006, 2007. Available at www.ginasthma.org.
   Google Scholar
• NivenRChungKFPanahlooZBloggMAyreGEffectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: An open-label studyRespir Med20081021371137818657960
   PubMed Web of Science ®Google Scholar
• BousquetJRabeKHumbertMPredicting and evaluating response to omalizumab in patients with severe allergic asthmaRespir Med20071011483149217339107
   PubMed Web of Science ®Google Scholar
• AyreGAnthonissenCMartinCTurkFThomasKAssessment of a responder identification treatment algorithm for omalizumab in a naturalistic settingEur Respir J200730Suppl 51623sP3654
   Google Scholar
• O’ConnellEJThe burden of atopy and asthma in childrenAllergy200459Suppl 7871115245350
   PubMed Web of Science ®Google Scholar
• PearceNAït-KhaledNBeasleyRWorldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC)Thorax20076275876617504817
   PubMed Web of Science ®Google Scholar
• RabeKFVermeirePASorianoJBMaierWCClinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) studyEur Respir J20001680280711153575
   PubMed Web of Science ®Google Scholar
• ChippsBESzeflerSJSimonsFEDemographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthmaJ Allergy Clin Immunol20071191156116317397912
   PubMed Web of Science ®Google Scholar
• MilgromHBergerWNayakATreatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)Pediatrics2001108E3611483846
   PubMed Web of Science ®Google Scholar
• LemanskeRFJrNayakAMcAlaryMEverhardFFowler-TaylorAGuptaNOmalizumab improves asthma-related quality of life in children with allergic asthmaPediatrics2002110e5512415061
   PubMed Web of Science ®Google Scholar
• LanierRBridgesTKulusMEfficacy and safety of omalizumab added to optimized asthma care in children with inadequately controlled allergic asthma. [abstract]Ann Allergy Asthma Immunol2009102A40
   Google Scholar
• TogiasARhinitis and asthma: evidence for respiratory system integrationJ Allergy Clin Immunol20031111171118312789212
   PubMed Web of Science ®Google Scholar
• PetersSPThe impact of comorbid atopic disease on asthma: clinical expression and treatmentJ Asthma20074449161
   Web of Science ®Google Scholar
• ChervinskyPCasaleTTownleyROmalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitisAnn Allergy Asthma Immunol20039116016712952110
   PubMed Web of Science ®Google Scholar
• HumbertMBouletLPNivenRMPanahlooZBloggMAyreGOmalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitisAllergy200964818419076535
   PubMed Web of Science ®Google Scholar
• BousquetPJDemolyPPassalacquaGCanonicaGWBousquetJImmunotherapy: clinical trials – optimal trial and clinical outcomesCurr Opin Allergy Clin Immunol2007756156617989535
   PubMed Web of Science ®Google Scholar
• CasaleTBBusseWWKlineJNOmalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitisJ Allergy Clin Immunol200611713414016387596
   PubMed Web of Science ®Google Scholar
• KuehrJBrauburgerJZielenSEfficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitisJ Allergy Clin Immunol200210927428011842297
   PubMed Web of Science ®Google Scholar
• Rolinck-WerninghausCHamelmannEKeilTThe co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic childrenAllergy20045997397915291906
   PubMed Web of Science ®Google Scholar
• KoppMVHamelmannEZielenSCombination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and comorbid seasonal allergic asthmaClin Exp Allergy20093927127919016798
   PubMed Web of Science ®Google Scholar
• LeynadierFDoudouOGaouarHEffect of omalizumab in health care workers with occupational latex allergyJ Allergy Clin Immunol200411336036114767458
   PubMed Web of Science ®Google Scholar
• SussmanGLessons learned from latex allergyAnn Allergy Asthma Immunol20039151051114700431
   PubMed Web of Science ®Google Scholar
• LeungDYSampsonHAYungingerJWEffect of anti-IgE therapy in patients with peanut allergyN Engl J Med200334898699312637608
   PubMed Web of Science ®Google Scholar
• DaveSCherryWBMaddoxDEOmalizumab therapy in evolving allergic bronchopulmonary aspergillosis [abstract]J Allergy Clin Immunol2007119S21
   Web of Science ®Google Scholar
• GeidelCSchulerDWeberKAnti-IgE therapy for cystic fibrosis patients with difficulties in treating allergic bronchopulmonary aspergillosis [abstract]J Cyst Fibros20076S14
   Google Scholar
• HsuRTKlaustermeyerWBOmalizumab for the treatment of allergic bronchopulmonary aspergillosis (ABPA) [abstract]Ann Allergy Asthma Immunol200698A36
   Web of Science ®Google Scholar
• van der EntCKHoekstraHRijkersGTSuccessful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibodyThorax20076227627717329558
   PubMed Web of Science ®Google Scholar
• WrayCJStenbitAEUse of omalizumab for cessation of corticosteroid therapy in a patient with pulmonary sarcoidosis, aspergillomas, long-standing asthma, and allergic bronchopulmonary aspergillosis [abstract]J Investigat Med2006164P494
   Google Scholar
• ZirbesJMillaCEExperience with the use of omalizumab in the management of severe allergic bronchopulmonary aspergillosis in 3 children with CFNorth American Cystic Fibrosis ConferenceDenver, Colorado2006373
   Google Scholar
• ForoughiSFosterBKimNAnti-IgE treatment of eosinophil-associated gastrointestinal disordersJ Allergy Clin Immunol200712059460117765756
   PubMed Web of Science ®Google Scholar
• KaplanAPJosephKMaykutRJGebaGPZeldinRKTreatment of chronic autoimmune urticaria with omalizumabJ Allergy Clin Immunol200812256957318774392
   PubMed Web of Science ®Google Scholar
• ZeldinRMassanariMBloggMJimenezPGebaGTreatment of moderate-severe asthma with omalizumab is associated with a decrease in peripheral blood eosinophils [abstract]Eur Respir J200730Suppl 51353s
   Google Scholar
• LeungDYMartinRJSzeflerSJDysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthmaJ Exp Med199518133407807013
   PubMed Web of Science ®Google Scholar
• NogaOHanfGKunkelGImmunological and clinical changes in allergic asthmatics following treatment with omalizumabInt Arch Allergy Immunol2003131465212759489
   PubMed Web of Science ®Google Scholar
• NogaOHanfGBrachmannIEffect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthmaJ Allergy Clin Immunol20061171493149916751018
   PubMed Web of Science ®Google Scholar
• NogaOHanfGKunkelGKleine-TebbeJBasophil histamine release decreases during omalizumab therapy in allergic asthmaticsInt Arch Allergy Immunol2008146667018087163
   PubMed Web of Science ®Google Scholar
• FeuchtingerTBartzHVonBATreatment with omalizumab normalizes the number of myeloid dendritic cells during the grass pollen seasonJ Allergy Clin Immunol200311142843012589369
   PubMed Web of Science ®Google Scholar
• BezCSchubertRKoppMEffect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitisClin Exp Allergy2004341079108515248853
   PubMed Web of Science ®Google Scholar
• HolgateSCasaleTWenzelSBousquetJDenizYReisnerCThe anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammationJ Allergy Clin Immunol200511545946515753888
   PubMed Web of Science ®Google Scholar
• CorrenJCasaleTLanierBBuhlRHolgateSJimenezPSafety and tolerability of omalizumabClin Exp Allergy2009In press.
   Google Scholar
• FernándezCBusseWReisnerCGuptaNClinical data do not suggest a causal relationship between omalizumab therapy and cancerProc Am Thorac Soc20052A359
   Google Scholar
• LimbSLStarkePRLeeCEChowdhuryBADelayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthmaJ Allergy Clin Immunol20071201378138117936893
   PubMed Web of Science ®Google Scholar
• CoxLPlatts-MillsTAFinegoldISchwartzLBSimonsFEWallaceDVAmerican Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxisJ Allergy Clin Immunol20071201373137717996286
   PubMed Web of Science ®Google Scholar
• BergerWGuptaNMcAlaryMFowler-TaylorAEvaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthmaAnn Allergy Asthma Immunol20039118218812952113
   PubMed Web of Science ®Google Scholar
• Scottish Medicines ConsortiumAdvice on omalizumab Available at http://www.scottishmedicines.org.uk/smc/5596.html. Accessed 6 March 2009.
   Google Scholar
• BrownRTurkFDalePBousquetJCost-effectiveness of omalizumab in patients with severe persistent allergic asthmaAllergy20076214915317298423
   PubMed Web of Science ®Google Scholar
• BrownRTurkFGrootMDalePCost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands [abstract]Eur Respir J200730194s
   PubMed Web of Science ®Google Scholar
• DewildeSTurkFTambourMSandstromTThe economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to SwedenCurr Med Res Opin2006221765177616968580
   PubMed Web of Science ®Google Scholar
• SullivanSDTurkFAn evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthmaAllergy20086367068418445184
   PubMed Web of Science ®Google Scholar
• ObaYSalzmanGACost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthmaJ Allergy Clin Immunol200411426526915316501
   PubMed Web of Science ®Google Scholar
• WuACPaltielADKuntzKMWeissSTFuhlbriggeALCost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy ModelJ Allergy Clin Immunol20071201146115217904628
   PubMed Web of Science ®Google Scholar
• MolimardMde BlayFDidierALe GrosVEffectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in FranceRespir Med2008102717617920257
   PubMed Web of Science ®Google Scholar
• MolimardMNivenRLe GrosVMcBryanDPanahlooZThirlwellJThe Anglo-French real-life experience of maintenance OCS use in omalizumab-treated patients with severe persistent allergic asthma [abstract]Eur Respir J200832Suppl 52345s
   Google Scholar
• MolimardMNivenRBuhlREuropean real-life experience of omalizumab (Xolair) and maintenance oral corticosteroid use in patients with severe persistent allergic asthma [abstract]J Allergy Clin Immunol20091232S156
   Web of Science ®Google Scholar
• KornSThielenASeyfriedSTreatment of uncontrolled, severe persistent allergic (IgE-mediated) asthma with omalizumab in a real-life setting in Germany [abstract]Eur Respir J200832Suppl 52345s
   Google Scholar
• RiviereG-JKueblerPJaffeJSYehC-MReynoldsCBrookmanLA liquid formulation of omalizumab is bioequivalent to the current lyophilized formulationAm J Respir Crit Care Med2008177Abstracts issueA613
   Google Scholar
• LowePJTannenbaumSGautierAJimenezPRelationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE mediated) asthmaBr J Clin Pharmacol2009In press.
   Google Scholar
• SlavinRFerioliCTannenbaumSAsthma symptom re-emergence after omalizumab withdrawal correlates well with increasing immunoglobulin-E and decreasing pharmacokinetic concentrationsJ Allergy Clin Immunol2009123107113.e319130931
   PubMed Web of Science ®Google Scholar
• NoppAJohanssonSGAnkerstJPalmqvistMOmanHCD-sens and clinical changes during withdrawal of Xolair after 6 years of treatmentAllergy2007621175118117845588
   PubMed Web of Science ®Google Scholar
• LowePJTannenbaumSGautierAMassanariMPanahlooZOmalizumab (Xolair) may normalize IgE production rate in patients with moderate-to-severe atopic asthma [abstract]J Allergy Clin Immunol20091232S152
   Web of Science ®Google Scholar